Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial

Inclusion Criteria: * Histologic evidence of EE defined as greater than 20 eosinophils per hpf on esophageal biopsy * Ages 1 yrs and older * Ability to continue the same diet that the patient was on at the time of EGD with biopsy Exclusion Criteria: * Adverse reaction or allergy to budesonide * Pregnancy * Chronic diseases requiring immunomodulatory therapy * Use of swallowed topical corticosteroids for EE within the past 3 months * Use of systemic steroids 2 months prior to study entry * Upper gastrointestinal bleed within 4 months of study entry * Chronic use of medications that predispose to upper gastrointestinal bleeding including non-steroidal anti-inflammatory medications or anticoagulants * Evidence of adrenal suppression prior to study entry * Evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis * Recent changes in asthma or allergic rhinitis therapy for 3 months